#27 - Pharmacology of drugs

A special treat this week as the two titans of psychopharmacology discuss the medicinal chemistry of psychedelics. Dr Nichols is the Founding President of the Heffter Research Institute, an organisation designed to promote research of the highest scientific quality with psychedelics in order to contribute to a greater understanding of the mind leading to the  …


Medical cannabis in the UK: From principle to practice

Authors: Anne Katrin Schlag, David S Baldwin, Michael Barnes, Steve Bazire, Rachel Coathup, H Valerie Curran, Rupert McShane, Lawrence D Phillips, Ilina Singh, David J Nutt Published: June 10, 2020 Read the full paper here (open access) Drug Science submits it's finding concerning the UK Medical cannabis industry. In our recent peer-reviewed publication, Drug Science  …

#19 - DMT

  DMT is a drug that’s relatively novel in western neuropsychopharmacology. Not much research has been done on this substance to date and many intoxicants are unable to recount their psychedelic experience. For the first time, this substance is being studied in an fMRI and EEG to elucidate why and how this drug elucidates vivid  …


#10 - MDMA-Assisted therapy

Dr Ben Sessa was the first doctor to administer MDMA assisted therapy in the 21st century and Christopher Trudgian was one of his very first patients. They both join Professor David Nutt to answer the question… can MDMA be used therapeutically to treat addiction and/or PTSD? The links between childhood trauma/PTSD and adult addiction are very  …


#8 - Medical Cannabis, Mum and Me

Lucy Stafford is a medical cannabis patient and advocate. Having spent most of her teenage years in severe pain, dependent on opiates and a feeding tube, discovering medical cannabis has transformed her health and quality of life. She is passionate about working towards a healthcare system that integrates the use of medical cannabis in the  …


Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts

Authors: Natasha L Mason, Patrick C Dolder, Kim PC Kuypers Published: January 30, 2020 Background It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting  …

2018: A watershed year for psychedelic science

Authors: Jacob S Aday, Christopher C Davoli, Emily K Bloesch Published: September 3, 2019 While interest in the study of psychedelic drugs has increased over much of the last decade, in this article, we argue that 2018 marked the true turning point for the field. Substantive advances in the scientific, public, and regulatory communities in  …

NICE on cannabidiol for childhood epilepsy

At the end of last week, NICE released their initial appraisal on cannabidiol in the form of Epidiolex for childhood epilepsy.  As predicted by Drug Science experts they found against it on the grounds of cost-benefit. We don’t have the company submission regarding cost/benefit analysis, and consequently cannot comment on those, but we can reflect  …


First safety study of MDMA-assisted psychotherapy in patients with alcohol use disorder

Authors: Ben Sessa, Chloe Sakal, Steve O’Brien and David Nutt Published: July 15, 2019 Read the full paper here (open access) We present the preliminary data in the Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, an ongoing open-label safety and tolerability proof of concept study exploring the potential role for 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in treating patients with alcohol  …

ACMD advice on cannabis-derived medicinal products

On 11 September 2018, the ACMD published its Advice to the Home Secretary and to the Secretary of State for Health and Social Care. It is a constructive document that highlights a number of issues and problems that this commentator has raised for some time. In some respects the document is nuanced. Doubtless in the  …

The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985)

3,4-Methylenedioxymethamphetamine (MDMA), also known as ecstasy, was first synthesized in 1912 but first reached widespread popularity as a legal alternative after the much sought-after recreational drug 3,4-methylenedioxy-amphetamine (MDA) was made illegal in 1970. Because of its benign, feeling-enhancing, and nonhallucinatory properties, MDMA was used by a few dozen psychotherapists in the United States between 1977  …


Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy

The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into  …


Ketamine treatment for depression

A review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The review concludes that further restrictions around ketamine are not neccesary and provides a set of recomendations for oversight bodies that would support safe, effective, and ethical use. Read it here

Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future

This special issue of the Journal of Psychopharmacology contains two landmark studies – the most rigorous controlled trials to date using the psychedelic drug psilocybin, the active ingredient of magic mushrooms (Griffiths et al., 2016; Ross et al., 2016). These were conducted in patients with anxiety and depression and existential distress in the context of  …

Cannabis Review for the attention of the WHO

Read the full report The scheduling under the Single Convention on Narcotic Drugs assumes a scientific justification. However, cannabis and cannabis resin have never been evaluated by the World Health Organisation (WHO) since it was mandated the review of psychoactive substances in 1948. The last evaluation for the international substance control conventions were therefore when  …

Ketamine as an essential medicine

Authors: Polly Taylor, David Nutt, Val Curran, Rudi Fortson, and Graeme Henderson Published: March 11, 2016 A letter to The Lancet endorsing the WHO Expert Committee on Drug Dependence's conclusion that concerns over recreational ketamine abuse in no way outweigh ketamine's role as a life-saving anasthetic and essential medicine. For open-access to the full report  …

Underground MDMA-, LSD- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary

Underground psychedelic-assisted psychotherapy has persisted in Europe despite the banning of the substances LSD and MDMA in the 1960s and 1980s, respectively. This article describes the work of a Zurich-based psychotherapist providing individual and group psycholytic psychotherapy, whose practice persisted for several years before she was arrested in 2009. The article provides commentary on the  …


The UK needs common sense about ketamine

A version of this post was published in The Guardian Ketamine is a unique anaesthetic and analgesic that has unfortunately become a popular and harmful recreational drug. Last year, in an attempt to reduce recreational use, and on the recommendation of its Advisory Council on the Misuse of Drugs (ACMD), the UK government decided to  …